Delivery Order HHSN261201600020I-HHSN26100001

This is a $1,010.00 firm fixed-price delivery order awarded by the National Cancer Institute (NCI) to the IIT Research Institute (IITRI), a non-profit contract research organization. The contract is for a "Kick Off Meeting, Preclinical Pharmacokinetic & Pharmacology Evaluations of Agents Being Developed for Cancer Patients" with a performance period from July 1, 2016 to September 30, 2016. This work is being performed under NCI's Pharmacokinetic and Pharmacology Evaluations for...

Mayo Clinic is providing research and development services as the prime contractor on a $167,149.99 delivery order against the National Cancer Institute's Pharmacokinetic and Pharmacology Evaluations for Cancer Patients indefinite delivery contract. This order is for Milestone 3 of preclinical pharmacokinetic studies with selected anticancer compounds in mice, including pharmacokinetic and pharmacology evaluations of agents being developed for cancer patients. The goal is to aid development...

This is a delivery order contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to IIT Research Institute (IITRI), a non-profit contract research organization. The $1,259,678.78 contract is to provide support for the preclinical development of an endoxifen gel, including pharmacology, toxicology, and safety studies to support an Investigational New Drug (IND) application. This contract is part of the NCI's PREVENT...

This federal contract award with award ID HHSN261201500024I|HHSN26100003 was issued by the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services (HHS). The $321,110.80 award was made on September 15, 2016 to the IIT Research Institute (IITRI), a non-profit research organization and division of the Illinois Institute of Technology (IIT). The contract is for the "PRECLINICAL EVALUATION OF A NEW LIPID-BASED SMEDDS" under the NCI's PREVENT...

This is a firm-fixed price delivery order awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Mayo Clinic, a renowned non-profit academic medical center. The contract is for $1,603.00 and covers pre-clinical pharmacokinetic and pharmacology evaluations of cancer therapeutic agents being developed under the NCI's Experimental Therapeutics program. This work supports the transition of promising cancer treatments from the laboratory to early...

The Department of Health and Human Services (HHS) National Cancer Institute awarded a $67,683 firm-fixed-price delivery order contract to the University of Pittsburgh to provide analytical support and pharmacokinetic (PK) sample analysis for preclinical pharmacology studies of agents being developed for cancer patients. The contract has a period of performance from September 16, 2019 to September 15, 2024 and is part of the larger Pharmacokinetic and Pharmacology Evaluations for Cancer...

This is a delivery order under the Toxicology of Drugs Developed for Cancer Patients contract vehicle, awarded by the National Cancer Institute (NCI) to Battelle Memorial Institute. The $248,269.21 cost-plus-fixed-fee contract is for a pre-clinical toxicity study to characterize the toxicity of potential anticancer compounds following multiple dose administration to rats. The contract runs from January 18, 2017 to June 30, 2018. No set-aside designation is mentioned. Battelle frequently serves...

This is a cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute (NCI), a civilian agency, to the University of Illinois. The contract is valued at $761,043.02 and is part of the larger "Toxicology of Drugs Developed for Cancer Patients" indefinite delivery/indefinite quantity (IDIQ) contract vehicle. The purpose of this award is to conduct pre-clinical toxicology studies of a drug candidate, specifically DNA methyltransferase-TdCyd, for potential use in...

This is a delivery order awarded by the National Cancer Institute (NCI), a component of the Department of Health and Human Services, to Mayo Clinic, a large non-profit academic medical center. The five-year, $204,622.95 contract supports pharmacokinetic and bioavailability studies of selected anticancer compounds in mice, which will provide analytical support to the NCI's Experimental Therapeutics program. Mayo Clinic is conducting these preclinical evaluations under a larger $9.9 million...

This is a federal contract award made by the National Cancer Institute (NCI), a civilian agency, to the University of Pittsburgh. The contract is for the determination of LMP744 (NSC 706744) levels in human plasma and urine samples from an NCI Phase I trial. The contract has a ceiling value of $408,140.33 and a period of performance from April 1, 2017 to June 30, 2022. It is a delivery order contract under the Pharmacokinetic and Pharmacology Evaluations for Cancer Patients master IDIQ. The...